The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2020

Filed:

Sep. 22, 2017
Applicant:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Ian Armitage, Medford, MA (US);

Eric L. Elliott, Brighton, MA (US);

Marianne Langston, North Andover, MA (US);

Steven P. Langston, North Andover, MA (US);

Quentin J. McCubbin, Belmont, MA (US);

Hiro Mizutani, Cambridge, MA (US);

Matthew Stirling, Boston, MA (US);

Lei Zhu, Bedford, MA (US);

Assignee:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07C 215/44 (2006.01); C07C 217/52 (2006.01); C07C 219/24 (2006.01); C07D 211/96 (2006.01); C07D 213/89 (2006.01); C07D 241/50 (2006.01); C07D 295/22 (2006.01); C07D 471/08 (2006.01); C07C 315/04 (2006.01); C07C 317/50 (2006.01); C07D 305/08 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07C 215/44 (2013.01); C07C 217/52 (2013.01); C07C 219/24 (2013.01); C07C 315/04 (2013.01); C07C 317/50 (2013.01); C07D 211/96 (2013.01); C07D 213/89 (2013.01); C07D 241/50 (2013.01); C07D 295/22 (2013.01); C07D 305/08 (2013.01); C07D 471/08 (2013.01); C07C 2601/08 (2017.05); Y02P 20/55 (2015.11);
Abstract

The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.


Find Patent Forward Citations

Loading…